ATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the pricing of an underwritten public offering of 10,434,586 shares of its common stock, or in lieu thereof, pre-funded warrants to purchase up to 11,750,000 shares of its common stock, together with accompanying common warrants to purchase up to an aggregate of 22,184,586 shares of its common stock. The combined public offering price for each share of common stock and accompanying common warrant is $0.36, except for 87,363 shares and accompanying warrants sold to certain officers of the Company at a price of $0.5151 per share and accompanying warrant. The combined offering price of each pre-funded warrant and accompanying common warrant is $0.3599. Each accompanying common warran
Related Questions
How will the dilution from the 10,434,586 shares/pre‑funded warrants and accompanying warrants affect FEMY’s earnings per share and existing shareholders?
What are the specific uses of the $8 million proceeds and how will they impact the company’s cash runway and upcoming product milestones?
How does the offering price and structure (including the $0.5151 price for officer shares) compare to recent equity raises by peer biotech companies, and what does that suggest for near‑term price pressure?